Eupraxia Pharmaceuticals (NASDAQ:EPRX) Posts Quarterly Earnings Results

Eupraxia Pharmaceuticals (NASDAQ:EPRX) issued its quarterly earnings results on Tuesday. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.03, Zacks reports.

Eupraxia Pharmaceuticals Stock Up 2.8%

Shares of EPRX traded up $0.21 during midday trading on Tuesday, reaching $7.63. 475,810 shares of the stock were exchanged, compared to its average volume of 388,924. The company has a market cap of $513.04 million, a price-to-earnings ratio of -7.48 and a beta of 1.04. The firm has a 50 day simple moving average of $7.56 and a 200-day simple moving average of $7.26. Eupraxia Pharmaceuticals has a 12-month low of $5.63 and a 12-month high of $9.32. The company has a quick ratio of 16.00, a current ratio of 16.00 and a debt-to-equity ratio of 0.02.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Royal Bank Of Canada assumed coverage on Eupraxia Pharmaceuticals in a research note on Monday. They set an “outperform” rating and a $14.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research note on Thursday, October 15th. Cantor Fitzgerald restated an “overweight” rating on shares of Eupraxia Pharmaceuticals in a report on Thursday, October 8th. HC Wainwright reissued a “buy” rating and set a $11.00 price target on shares of Eupraxia Pharmaceuticals in a research report on Thursday, October 1st. Finally, Wall Street Zen downgraded shares of Eupraxia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Sunday. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $17.17.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc. is a Canadian clinical-stage biopharmaceutical company focused on developing locally delivered therapies for chronic diseases. The company uses its proprietary DiffuSphere technology to formulate drug products designed to provide controlled, sustained release at targeted sites in the body, with the goal of improving treatment effectiveness and tolerability. Eupraxia’s lead development program, EP-262, is an intra-articular therapy being developed for osteoarthritis of the knee.